Acute myeloid leukemia with high ecotropic viral integration site-1 expression (EVI1 high AML) is classified as a refractory type of leukemia with a poor prognosis. To provide new insights into the prevention and treatment of this disease, we identified the high expression of EVI1-regulated G protein-coupled receptor 56 (GPR56), and the association of high cell adhesion and antiapoptotic activities in EVI1 high AML cells. Knockdown of GPR56 expression decreased the cellular adhesion ability through inactivation of RhoA signaling, resulting in a reduction of cellular growth rates and enhanced apoptosis. Moreover, in Gpr56 À / À mice, the number of hematopoietic stem cells (HSCs) was significantly decreased in the bone marrow (BM) and, conversely, was increased in the spleen, liver and peripheral blood. The number of Gpr56 À / À HSC progenitors in the G0/G1-phase was significantly reduced and was associated with impaired cellular adhesion. Finally, the loss of GPR56 function resulted in a reduction of the in vivo repopulating ability of the HSCs. In conclusion, GPR56 may represent an important GPCR for the maintenance of HSCs by acting as a co-ordinator of interactions with the BM osteosteal niche; furthermore, this receptor has the potential to become a novel molecular target in EVI1 high leukemia.
INTRODUCTION
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, and refractory AML is considered a stem cell disease. Leukemia stem cells (LSCs) are thought to be the hijack maintenance mechanisms of hematopoietic stem cells (HSCs) in the bone marrow (BM), and consequently to contribute to eventual disease relapse after they have survived undetected in the BM niche during chemotherapy. 1, 2 Therefore, if the adhesion molecules specific for LSC maintenance in the BM niche can be found, targeting these interaction molecules between LSC and the surrounding support cells could represent a promising and novel therapeutic strategy for AML.
The ecotropic viral integration site-1 (EVI1) transcription factor is a well-known marker of poor prognosis for chemotherapyresistant AML. [3] [4] [5] [6] [7] [8] The gene expression profiles found in acute myeloid leukemia with high ecotropic viral integration site-1 expression (EVI1 high AML) patients are quite similar to those of BM CD34 þ cells; 9, 10 EVI1 is implicated in stem cell regulation and oncogenesis, and contributes to the poor clinical outcome of AML by promoting stemness.
11 EVI1 maintains the self-renewal capacity of embryonic HSCs by activating Gata2 transcription, 12 and the ablation of EVI1 in adult BM leads to a significant decrease in the numbers of HSCs. 13 Therefore, EVI1 may have an important role in the maintenance of cell quiescence and stem cell-like phenotypes in leukemia cells, thereby contributing to their chemoresistance.
To identify novel therapeutic molecules targeting EVI1 high AML cells, we analyzed the gene expression profiles of these molecules and the newly identified G protein-coupled receptor 56 (GPR56) as a candidate target molecule for EVI1 high AML cells, along with CD52, integrin a6 and Angiopoietin-1. [14] [15] [16] GPR56 is a member of the secretin family and has been linked to developmental malformations of the human brain, known as bilateral frontoparietal polymicrogyria. [17] [18] [19] GPR56, coupled with Ga 12/13 , induces Rho-dependent activation of transcription, resulting in actin fiber reorganization and inhibition of neural progenitor cell migration. 20 In cancer cells, overexpression of GPR56 can suppress tumor growth and metastasis in melanoma cell lines, and GPR56 functions in tumor cell adhesion in glioma cells. [21] [22] [23] Although the function of GPR56 in HSCs is still unknown, 24 GPR56 was also identified in a family of LSC-related genes correlated with a worse prognosis of AML.
11 GPR56 regulates RhoA signaling involved in cellular adhesion, and the small GTPases Rac and Cdc42 control HSC adhesion, migration and mobilization in BM niches; [25] [26] [27] [28] [29] [30] therefore, we speculated that GPR56 has an important role in the maintenance of HSCs and/or LSCs in the BM niche.
In this study, we found that GPR56 was specifically expressed in EVI1
high AML cells as an EVI1-targeted gene and was associated with high cell adhesion and antiapoptotic activities in the leukemia cells. To further define the role of GPR56 in HSC regulation, we analyzed the function of HSCs in Gpr56 À / À mice, and our results demonstrated a role of Gpr56 in maintaining HSC quiescence and osteosteal niche interactions in the BM. Because the expression of GPR56 in LSCs is higher than in HSCs, GPR56 has potential as a novel therapeutic target for EVI1 high AML.
MATERIALS AND METHODS

Cell lines
UCSD/AML1 and HNT34 cells were cultured in RPMI1640 (Roswell Park Memorial Institute medium) supplemented with 10% fetal calf serum and 1 ng/ml of human granulocyte-macrophage (GM) colony-stimulating factor. U937 and K562 cells were cultured in RPMI1640 supplemented with 10% fetal calf serum, and 293T cells were cultured in Dulbecco's modified eagle medium supplemented with 10% fetal calf serum.
Detailed information concerning our cell lines is available as described previously. Quantitative real-time reverse-transcription PCR After extraction of total RNA using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA), 1 mg of total RNA was reverse transcribed to produce complementary DNA using Reverse Transcriptase XL (AMV, avian myeloblastosis virus) (Takara-Bio Inc., Tokyo, Japan). The resulting firststrand complementary DNA was used as a template for real-time PCR. Realtime PCR was performed using MESA GREEN qPCR MasterMix Plus for SYBR assay (EUROGENTEC, Seraing, Belgium). The primers used in these experiments are listed in Supplementary Table 2 . The mRNA expression levels of several genes were detected using an ABI Prism 7000 (Applied Biosystems, Foster City, CA, USA), and the data obtained were analyzed with Sequence Detection System software (Applied Biosystems) and normalized to b-actin.
Mice
Gpr56
À / À mice were kindly provided by Genentech (South San Francisco, CA, USA). 18, 19, 31 C57BL/6 CD45.1 congenic mice (B6-CD45.1) were purchased from Sankyo-Lab Service (Tsukuba, Japan). For analysis of blood counts, peripheral blood (PB) from the tail vein was collected in a heparinized microtube and analyzed on a hematology analyzer (CellTac, NIHON KOHDEN, Tokyo, Japan).
Isolation of murine HSCs and flow cytometry BM was collected from femurs and tibiae. Lin þ cells were removed by immunomagnetic selection using AutoMACS magnetic-activated cell separation (Auto MACS, Miltenyi Biotec, Bergisch, Gladbach, Germany). Lin À cells were enriched for cells expressing c-Kit using Miltenyi CD117 microbeads and an AutoMACS magnetic selection device. The HSCs and myeloid progenitors were sorted by first staining Lin À BM cells with Alexa Fluor 647-conjugated anti-CD34 (RAM34; BD Bioscience, Franklin Lakes, NJ, USA), PerCP-Cy5.5-conjugated anti-CD16/32 (93; eBioscience, San Diego, CA, USA), PE-Cy5-conjugated anti-Flk2 (A2F10; eBioscience) and biotinylated anti-mGpr56 antibodies, followed by streptavidin-Allophycocyanin (APC)/Cy7 (BioLegend, San Diego, CA, USA). A rabbit anti-mGpr56 antibody was used as described previously. 20 Cells were then sorted using a JSAN cell sorter (Bay bioscience, Kobe, Japan).
RESULTS
High expression of GPR56 in EVI1
high AML cells
To search for novel molecular targets for EVI1 high AML, we recently analyzed the gene expression profiles of 12 human myeloid cell lines using an oligonucleotide microarray; from this analysis, GPR56 was identified. 14, 15 In the present study, we focused on the analysis of GPR56, an orphan G protein-coupled receptor. Initially, we used quantitative real-time PCR to measure the expression of EVI1 and GPR56 in a panel of leukemia cell lines and primary leukemia samples (Figures 1a and b) . Our results revealed that GPR56 mRNA was significantly more highly expressed in the EVI1 high leukemia cell lines and patient samples than in their EVI1 low counterparts (Po0.05), and the expression of GPR56 was highly correlated with the expression of EVI1 (Figures 1a and b) . Furthermore, based on gene expression profiles from a large number of patients with AML (n ¼ 460) (accession number GSE6891), 10 GPR56 was highly expressed in EVI1 high AML cells compared with EVI1 low AML cells (Supplementary Figure 1a) . In addition, the GPR56 mRNA level associated with intermediateand high-risk AML samples was significantly higher than that in the low-risk AML samples (Supplementary Figure 1b) , suggesting that GPR56 expression is a marker of poor prognosis in AML patients.
The expression of GPR56 was regulated by the EVI1 transcription factor To determine whether the expression of GPR56 is regulated by EVI1, we introduced an expression vector for EVI1-specific (shEVI1) or non-specific small hairpin RNA (shCNTL) into EVI1 high UCSD/ AML1 and PT9 cells to establish UCSD/AML1 and PT9 cells exhibiting EVI1 low expression (UCSD/AML1/shEVI1, PT9/shEVI1) and control cells (UCSD/AML1/shCNTL, PT9/shCNTL). The expression of GPR56 was significantly reduced in the UCSD/AML1/shEVI1 and PT9/shEVI1 cells compared with GPR56 expression in parental and control cells ( (Figures 1f-h ). To determine whether EVI1 regulates GPR56 expression, we next isolated a 3-kb fragment from the genomic promoter region of GPR56 and inserted it in front of the firefly luciferase gene (pGL4-3.0). We created promoter DNA deletion mutants by deleting the region up to À 1.5 (pGL4-1.5) or À 2.4 (pGL4-2.4) kb, and the promoter activity was determined via luciferase assays after transfection into COS7 cells (Figure 2a ). We found that the region between À 2.4 and À 3.0 kb markedly enhanced the promoter activity of GPR56 in the presence of transfected EVI1. In addition, a possible binding sequence for the second DNA-binding domain of EVI1, GAAGAT, was found in the region between À 2.4 and À 3.0 kb. This binding sequence was replaced with the nucleotide sequence CCCGAC in the pGL4-3.0 plasmid (pGL4-3.0 m), and the resultant mutant plasmid completely abolished GPR56 transcriptional activity. To confirm the DNA-binding activity of EVI1, several EVI1 deletion mutants were transfected into COS7 cells, and their GPR56 transcriptional activity was measured (Figure 2b ). The transcriptional activity of the mutant containing a deletion of the repression domain (DRD) showed less than half of the wild-type activity, and deletion of the second DNA-binding domain along with the eighth through the tenth zinc finger repeats (DD2 (8-10)) completely abolished GPR56 transcriptional activity. In addition, the DD2 (8-10) EVI1 mutant protein was not precipitated by the DNA fragment of the GPR56 promoter region in chromatin immunoprecipitation assays (Figure 2c) . Finally, the endogenous EVI1 protein was precipitated from UCSD/AML1 cells using the same GPR56 promoter region with the EVI1-binding site via chromatin immunoprecipitation with an anti-EVI1 antibody ( Figure 2d ). Therefore, EVI1 binds directly to the promoter region of GPR56 and regulates GPR56 expression in EVI1 high leukemia cells.
GPR56 regulated cell adhesion and migration in EVI1 high AML cells
Because high expression of GPR56 promotes tumorigenesis by enhancing the cellular adhesion of glioma cells, 21 we next compared the cell migration and adhesion abilities of leukemia HSC maintenance by EVI1-regulated GPR56 Y Saito et al The structures of wild-type EVI1 and the EVI1 mutants with a series of deleted domains are depicted. COS7 cells were co-transfected with the GPR56 reporter vector, and each expression vector was co-transfected with EVI1 or EVI1 mutants (DD1 (ZF1-7), DRD, or DD2 (ZF8-10)). The fold change was calculated by dividing the fold activation of each EVI1 mutant co-transfected with pGL4-3.0 by the fold activation of the respective EVI1 mutant co-transfected with pGL4-vec. All of the luciferase reporter assays were performed in duplicate in two independent experiments. The values and error bars depict the means±s.d. (c) Chromatin immunoprecipitation analysis of the EVI1-binding site in the GPR56 promoter region after transfection with the EVI1 expression vector is shown. After co-transfection with FLAG-tagged EVI1/WT or EVI1/ DD2 (ZF8-10) with pGL4-3.0, formalin-fixed DNA fragments were immunoprecipitated with an anti-FLAG antibody or control mouse immunoglobulin G. The precipitated DNA was then amplified using specific primers to detect the EVI1-binding sites. (d) Chromatin immunoprecipitation of the endogenous EVI1 protein from UCSD/AML1 cells is shown. Formalin-fixed DNA fragments were immunoprecipitated with an anti-EVI1 antibody or control mouse immunoglobulin G. The precipitated DNA was then amplified using specific primers to detect the EVI1-binding sites.
transfected with shGPR56 (PT9/shGPR56) ( Supplementary Figures  3a and b) . By contrast, the adhesion of U937/GPR56 cells was significantly increased compared with that of the parental and U937/Mock cells ( Supplementary Figures 3c and d) . To determine the cell migration abilities of the leukemia cells, the cells were added to the upper well of a Boyden chamber after fibronectin, laminin-1 or collagen type III had been embedded at the interface, and culture medium containing stromal cell-derived factor-1 was added to the bottom chamber. The number of migrating UCSD/ AML1/shGPR56 cells was significantly increased compared with that of the parental and UCSD/AML1/shCNTL cells in the three different types of coated chambers (Figure 3d ). Because the expression of CXCR4 was not significantly different between both cell types (Supplementary Figure 4) , the increased migration ability mainly depended on the adhesion ability of the cells to the extracellular matrix in a Boyden chamber.
Collagen type III and other extracellular matrix molecules induce activation of the small GTP-binding protein RhoA downstream of GPR56; 31 therefore, we next determined the protein levels of GTPbound RhoA in these cell lines. The level of GTP-bound RhoA in parental and UCSD/AML1/shCNTL cells was increased after stimulation by collagen type III. However, the GTP-bound RhoA content in nonstimulated AML/shGPR56 cells was lower than the content in control cell lines, and stimulation with collagen type III did not increase the amount of GTP-bound RhoA in AML/shGPR56 cells (Figure 3e ). To confirm whether activation of RhoA is necessary for the cellular adhesion of AML cells showing high GPR56 expression, Y-27632, a selective inhibitor of the Rho-associated protein kinase p160ROCK, was added to the culture medium of UCSD/AML1 cells. In control medium, UCSD/ AML1 cells attached to conventional culture plates with a spindle-shaped cell morphology. However, the morphology of UCSD/AML1 cells changed from dendritic to small and round after the treatment with Y-27632 (Supplementary Figure 5a) . In addition, the adhesion of UCSD/AML1 cells to MC3T3-E1 cells or to fibronectin was significantly decreased by treatment with Y-27632 (Supplementary Figure 5b) 4a and b) . Moreover, after introduction of the shGPR56 expression vector into PT9 cells, the colony-forming ability of parental PT9, PT9/shCNTL and PT9/shGPR56 cells was determined in methylcellulose cultures with GM-colony-stimulating factor. The colony number and size of granulocyte/macrophage colony-forming units were significantly reduced in PT9/shGPR56 cells ( Supplementary Figures 6a and b) . Therefore, we next determined whether apoptotic cell death was induced in shGPR56 cells. In a cell cycle analysis, an increase in the SubG1-phase cell population was observed in the UCSD/AML1/shGPR56 cells (Figure 4c ). To confirm the induction of apoptotic cell death by GPR56 knockdown, lentivirus-infected cells were analyzed via flow cytometry after double staining with 7-Aminoactinomycin D and phycoerythrin-conjugated Annexin V (Figures 4d and e) . The population of apoptotic cell death in the UCSD/AML1/shGPR56 cells was significantly increased compared with that in the UCSD/AML1/shCNTL cells several days after lentiviral infection, suggesting that the apoptosis of the UCSD/AML1/ shGPR56 cells was due to the reduction of GPR56 expression. To determine the molecular mechanism underlying the inhibition of the apoptosis pathway downstream of GPR56 signaling, we determined the protein expression status of known apoptotic indicators and cell cycle regulators, including p53 and caspase-3 ( Figure 4f ). Cleaved caspase-3 fragments were detected in UCSD/ AML1/shGPR56 cells, indicating that the apoptotic pathway was activated. Interestingly, the protein levels of p53, p21 and p27 were increased in UCSD/AML1/shGPR56 cells, whereas the level of MDM2 was proportionally decreased. However, the mRNA levels of p53 and MDM2 were unchanged in UCSD/AML1/shGPR56 cells compared with control UCSD/AML1 cells (Supplementary Figure 7) , suggesting that an unknown signaling pathway downstream of GPR56 may stabilize the level of the MDM2 protein in EVI1 high AML cells, which promotes cell survival by promoting p53 degradation.
GPR56 expression was related to cell adhesion mediated drug resistance and the invasion ability of leukemic cells in BM We next examined the role of GPR56 expression in the drug sensitivity of the cells to anticancer drugs. The UCSD/AML1 cells were seeded on MC3T3-E1 or BSA with various concentrations of Ara-C or daunorubicin (DNR) in culture media. Twenty-four hours after incubation, the percentages of surviving UCSD/AML1/ shGPR56 cells on MC3T3-E1 cells (adherent status) were significantly reduced compared to the control UCSD/AML1 cells; however, the percentages of the UCSD/AML1/shGPR56 cells that survived under conventional culture condition were not different between the cells (Figures 5a and b) . To determine the role of GPR56 expression in drug resistance in vivo, we performed xenotransplantation experiments of leukemia cells with high or low GPR56 expression into non-obese diabetic-severe combined immunodeficiency/gcnull (NOD-SCID/gcnull, NOG) mice. Initially, we determined the percentages of invaded leukemia cells in various organs two weeks after transplantation. Leukemia cells with high GPR56 expression (K562/GPR56 and UCSD/AML1) had a tendency to infiltrate into the BM more than other organs; however, leukemia cells with low GPR56 expression (K562/Mock and UCSD/AML1/shGPR56) infiltrated to the PB and other organs more than the BM (Figures 5c and d) . To find the different effects of anticancer drugs on leukemia cells with high or low expression of GPR56 in vivo, mice transplanted with UCSD/AML1/shCNTL or UCSD/AML1/shGPR56 leukemia cells were treated with Ara-C for two weeks; at this time, the number of viable leukemia cells was determined in various organs by flow cytometry. The result showed that the USCD/AML1/shGPR56 cells were more effectively eliminated in the PB and spleen than in the BM (Figure 5e ). Although we did not determine the survival curve of xenotransplanted mice undergoing anticancer treatment, the reduction of GPR56 expression in leukemia cells may help to enhance the sensitivity to anticancer drugs; further studies are needed to examine these effects.
High GPR56 expression in murine hematopoietic stem cell fractions and decreased numbers of HSCs in the BM of Gpr56 À / À mice Because GPR56, regulated by EVI1, is speculated to have an important function in the maintenance of HSCs, we next examined the expression of GPR56 in myeloid lineage cells at various stages of differentiation via flow cytometry analysis. Over 90% of LSK (Lin À Sca-1 þ c-Kit þ ) cells expressed GPR56 on their cell surfaces, and more primitive self-renewing HSCs, including long-term and short-term HSCs, showed expression rates greater than 95% (Supplementary Table 3 and Supplementary Figure 8a) . The level of GPR56 expression gradually decreased during the myeloid differentiation stages, and less than 50% of Lin þ progenitor cells exhibited detectable GPR56 expression. In the BM in the diaphysis of tubular bones, high numbers of GPR56-positive cells were detected by fluorescence staining close to the periosteal rim, which is a region that contains potential BM osteosteal niches. The GPR56-positive mononuclear cells frequently coexpressed c-Kit and Sca-1, suggesting that GPR56 þ c-Kit þ primitive cells may localize near the periosteal region (Figure 6a and Supplementary  Figure 8b) . To determine the role of GPR56 in the regulation of hematopoiesis, we initially confirmed the downregulation of GPR56 expression in Lin Figure 9a) , and determined the hematological profiles in their PB. There were no differences in the blood cell counts or hemoglobin content between the wild-type and Gpr56 À / À mice (Supplementary Table 4 ). There were also no differences in whole-BM cells and spleen cells (Supplementary  Figure 9b) . Interestingly, the percentages of LSK cells in the BM were significantly decreased, but the percentages in the spleen and the PB were conversely increased in the Gpr56 À / À mice (Figures 6b and c) . Moreover, the populations of short-term HSCs and long-term-HSCs were significantly reduced among the BM cells of the Gpr56 À / À mice (Figure 6d ). In the next experiment, we determined the colony-forming ability of mononuclear cells from the BM, spleen, liver and PB using semi-solid culture with several specific cytokines (Figure 6e ). The number of granulocyte/ þ / þ ( þ / þ , white bar) and Gpr56 À / À ( À / À , gray bar) mice were determined in methylcellulose cultures by measuring granulocytes/monocytes colony-forming units(CFU-GM), erythroids (burst-forming unit-erythroid, BFU-E) and granulocytes/ erythroids/monocytes/megakaryocytes (CFU-GEMM). The data shown are the mean numbers of colonies (n ¼ 3).
granulocyte/macrophage colony-forming units were maintained in Gpr56
À / À mice, the numbers of white blood cells were most likely not decreased in Gpr56 À / À mice. Therefore, a part of the HSCs in Gpr56 À / À mice do not remain in the BM and relocate to the peripheral organs where they maintain their differentiation capacity.
Decreased cellular adhesion and increased cellular migration ability in HSCs from Gpr56 À / À mice To investigate whether the decreased number of HSCs in the BM is related to a reduction in their adhesion and acquisition of migration ability, we assessed cellular adhesion and the cell migration ability using BM precursor cells with the Lin À c-Kit þ / þ and Gpr56 À / À mice were administered 5-fluorouracil intraperitoneally once per week for 2 weeks, and the survival of individual mice was monitored daily. The results were analyzed using a log-rank nonparametric test, and the survival rates of 
phenotype. The BM precursor cells in Gpr56
À / À mice displayed decreased adhesion to MC3T3-E1 cells, fibronectin, laminin-1 and collagen type III as extracellular matrices (Figure 7a ). The ability of BM precursor cells from Gpr56 À / À mice to migrate towards the chemoattractant stromal cell-derived factor-1 was significantly increased on the three types of coated extracellular matrices (Figure 7b ). In the next experiment, we determined the precise localization of HSCs in the BM using confocal microscopy after staining BM sections with phycoerythrin-conjugated c-kit and fluorescein isothiocyanate-conjugated Sca-1 antibodies. The HSC maintenance by EVI1-regulated GPR56 Y Saito et al number of primitive cells located less than 20 mm from the periosteum was significantly decreased in the Gpr56 À / À mice (Figure 7c and Supplementary Figure 10) . By contrast, the number of cells that were located more than 50 mm from the periosteum was increased in the Gpr56 À / À mice. Finally, to investigate whether the migration and adhesion abilities of HSCs depend on GPR56 signaling through the Ga 12/13 and Rho signaling pathway, we determined the protein levels of GTP-bound RhoA in the HSC fractions of wild-type and Gpr56 À / À mice (Figure 7d ). High levels of GTP-bound RhoA accumulated in wild-type mice under both nonstimulated and collagen type III-stimulated conditions, although the stimulation mechanism was unknown in the HSC fraction of wild-type mice. Conversely, low levels of GTP-bound RhoA were detected in the Gpr56 À / À mice in both the untreated and collagen type III-treated BM cells. In addition, the ability of HSCs to adhere to MC3T3-E1 cells or to fibronectin was significantly decreased by the treatment with Y-27632, a p160ROCK kinase inhibitor (Supplementary Figures 11a and b) . Thus, the data suggest that the cellular adhesion of HSCs was decreased by the reduction of RhoA signaling activity, resulting in a reduction in HSCs near the periosteum.
The expression of GPR56 in HSCs was involved in the maintenance of quiescence and long-term BM reconstitution Because the fraction of LSK cells in Gpr56 À / À mice was decreased in the BM along with a reduction in their adhesion ability, we next investigated the fraction of apoptotic cells and cell cycle parameters in the LSK fraction in the BM. The Annexin V þ 7-7-aminoactinomycin D À fraction of apoptotic cells was significantly increased in Gpr56 À / À mice ( Figure 8a and Supplementary  Figure 12 ). The population of G0/G1-phase cells was also decreased, together with an increased population of S-phase cells in the Gpr56 À / À mice (Figure 8b) . Furthermore, the population of G0-phase cells separated by pyronin Y and Hoechst 33342 staining was significantly reduced in the LSK fraction in Gpr56 À / À mice compared with the population in wild-type mice (Figure 8c ). In the next experiment, to determine the drug sensitivity of BM cells in the Gpr56 À / À mice to an anticancer drug, 5-fluorouracil was injected at a dose of 150 mg/kg once per week for 2 weeks into each of six wild-type and Gpr56 À / À mice (Figure 8d ). The median lifespan of the wild-type mice was 10.5 days, whereas the lifespan of the Gpr56 À / À mice was significantly shortened to 7.5 days (Po0.05); this result suggests that the reduction of the HSC population in the BM and the decreased proportion of G0-phase cells resulted in enhanced cytotoxicity in the Gpr56 À / À mice in response to this anticancer drug. Finally, to define the ability of HSCs in the Gpr56 À / À mice to reconstitute hematopoiesis, a mixture of CD45.2 þ BM cells from wild-type or Gpr56 À / À mice with CD45.1 þ competitor BM cells was transplanted into lethally irradiated CD45.1 þ mice (Figure 8e ). In the first transplantation, the population of CD45.2 þ white blood cells from Gpr56 À / À mice in the PB was decreased in the recipients compared with the population in the wild-type mice (Figure 8f) . Moreover, the population of myeloid, erythroid, megakaryocyte and Lin -c-Kit þ BM cells from Gpr56 À / À mice in the recipient BM was significantly decreased (Figure 8g and Supplementary Figure 13 ). In the second transplantation, the population of white blood cells from Gpr56 À / À mice was significantly diminished in the PB and Lin -c-Kit þ BM cell fractions of the recipients (Figures 8h and i) . Furthermore, to confirm the reduced reconstitution ability of the stem cell fraction in the Gpr56 À / À mice, we transplanted 1 Â 10 4 LSK cells from wild-type or Gpr56 À / À mice with CD45.1 þ competitor BM cells into lethally irradiated CD45.1 þ mice. As shown in Figures 8j and k, the population of white blood cells from Gpr56 À / À mice was significantly decreased in the PB and Lin -c-Kit þ BM cell fractions of the recipients. Thus, the reduction of cell numbers and the depletion of the quiescent cell population in BM-derived HSCs may result in a reduced capacity for HSC reconstitution in Gpr56 À / À mice.
DISCUSSION
In this study, RhoA signaling through Ga 12/13 coupled with GPR56 is a novel signaling pathway for HSC maintenance in BM, which is regulated by EVI1. As high levels of GPR56 expression correlate with the cellular transformation phenotypes of several cancer tissues, [21] [22] [23] high expression of GPR56 in EVI1 high AML cells may result in apoptotic resistance with a poor prognosis.
Rac1/Rac2 and the Rho family GTPase Cdc42 previously have been implicated in the maintenance of HSCs through the regulation of adhesion, migration, homing and mobilization. HSCs from Cdc42-deficient mice exhibit impaired adhesion, homing, lodging and retention, leading to massive cellular egress from the BM to distal organs and PB, ultimately resulting in failure of engraftment. 25, 29 Rac-1-deficient HSCs show a significant reduction in hematopoietic reconstitution, without any effect on cellular adhesion. However, Rac2-deficient HSCs exhibit decreased cellular adhesion but normal short-term engraftment, suggesting a prominent role for Rac2 in integrin-mediated stem cell adhesion. [26] [27] [28] On the other hand, P190-B RhoGAP is a major regulator of Rho GTPases, and abnormally high levels of active RhoA protein were detected in embryo-derived cells from P190-Bdeficient mice. The migration and adhesion of hematopoietic progenitor cells from the P190-deficient mice were markedly enhanced in an in vitro experiment, and the high levels of active RhoA were associated with a significant enhancement of HSC engraftment and reconstitution in vivo. 32 In this study, we demonstrated that downregulation of GPR56 expression in EVI1 high leukemia cells and Gpr56 À / À LSK cells caused RhoA inactivation with a concomitant decrease in cellular adhesion. Moreover, apoptotic cell death and decreased G0 cell fractions in leukemia cells and HSC cells with low RhoA activity were found in both in vitro and in vivo experiments, and the inactivation of RhoA activity in HSC cells from Gpr56-deficient mice reduced the reconstitution ability. On the basis of the findings of P190-B-and GPR56-deficient mice, the level of RhoA activation may significantly influence the maintenance of the HSCs in BM.
Rac is activated by the stimulation of CXCR4 by stromal cellderived factor-1, by adhesion via b1 integrin, and by the stimulation of c-Kit by stem cell factors, all of which are involved in stem cell engraftment. However, no specific ligands of GPR56 other than collagen type III are currently known. Because the expression level of GPR56 was significantly higher in CD34 þ
CD38
-EVI1 high LSC fractions than in normal HSCs (Supplementary Figure 14) , GPR56 has the potential to become a novel molecular target in EVI1 high leukemia. The results of this study have led to a significant improvement in our understanding of stem cell retention in BM and trafficking in the peripheral circulation. Furthermore, if the specific ligand of GPR56 is identified, we will be able to develop a small-molecule inhibitor or antibody as a specific therapeutic target for refractory leukemia that could modulate the adhesion, mobilization and proliferation abilities of EVI1 high leukemia cells.
